CASSIOPEA SPA
- Country
- 🇮🇹Italy
- Ownership
- Public, Subsidiary
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cassiopea.com
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
- Conditions
- Alopecia, Androgenetic
- Interventions
- Drug: Vehicle solution
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 726
- Registration Number
- NCT05914805
- Locations
- 🇺🇸
Investigate MD, Scottsdale, Arizona, United States
🇺🇸Physician's Institute of Cosmetic and Reconstructive Surgery, Hollywood, Florida, United States
🇺🇸DelRicht Research, Thompson's Station, Tennessee, United States
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
- Conditions
- Alopecia, Androgenetic
- Interventions
- Drug: Vehicle solution
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 726
- Registration Number
- NCT05910450
- Locations
- 🇺🇸
The Petrus Center for Aesthetic Surgery and Hair Transplantation, North Little Rock, Arkansas, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Mayo Clinic, Department of Dermatology, Jacksonville, Florida, United States
A Study to Investigate the Effects of Cortexolone 17α-propionate (and Its Metabolites) on Healthy Volunteers' Heart
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 32
- Registration Number
- NCT03665194
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 27
- Registration Number
- NCT02720627
- Locations
- 🇺🇸
Site 103, Fort Smith, Arkansas, United States
🇺🇸Site 101, San Diego, California, United States
🇺🇸Site 102, Houston, Texas, United States
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- Drug: CB-03-01 cream, 1%
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 609
- Registration Number
- NCT02682264
- Locations
- 🇺🇸
Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸Gary M. Petrus, MD PA, Little Rock, Arkansas, United States
🇺🇸Center for Dermatology and Laser Surgery, Sacramento, California, United States
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
- Conditions
- Acne Vulgaris
- Interventions
- Drug: CB-03-01 cream, 1%Drug: Vehicle cream
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 732
- Registration Number
- NCT02608476
- Locations
- 🇺🇸
Clear dermatology & Aesthetic Center, Scottsdale, Arizona, United States
🇺🇸Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸Center for Dermatology and Laser Surgery, Sacramento, California, United States
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)
- Conditions
- Acne Vulgaris
- Interventions
- Drug: CB-03-01 cream, 1%Drug: Vehicle cream
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 708
- Registration Number
- NCT02608450
- Locations
- 🇺🇸
Gary M. Petrus, MD PA, Little Rock, Arkansas, United States
🇺🇸Center For Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, United States